Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Oncology: Big Strides But Not Blockbuster Size

Executive Summary

Pfizer’s emphasis on oncology has yielded three new drug approvals in the last 20 months and another two promising drugs on the horizon. It is a notable achievement, but investors may be wondering when the results are going to be felt on the top line.


Related Content

Deal Watch: Pfizer, BioAtla Team Up To Develop Targeted Antibody Oncologics
First-Line Breast Cancer Approval Opens The Door For Pfizer’s Palbociclib
Pfizer’s Dolsten Explains Why The Big Pharma Can Win The Immuno-Oncology Marathon
Bayer Looks For New Partner As It Strives To Be A Player In Oncology Market
Three For The Citi: Pfizer, Bristol, GSK Provide R&D, Pricing Briefings
Pfizer Oncology Pipeline Takes Hit With Dacomitinib Lung Failure
Pfizer Breast Cancer Drug Could Fill Void Left By Avastin Withdrawal
Xalkori And Zelboraf: The Highs And Lows Of Commercializing Targeted Cancer Drugs
Pfizer’s Crizotinib Eases Past FDA With Targeted Population
With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts